1
|
Alessenko AV, Gutner UA, Shupik MA. Involvement of Lipids in the Pathogenesis of Amyotrophic Lateral Sclerosis. Life (Basel) 2023; 13:life13020510. [PMID: 36836867 PMCID: PMC9966871 DOI: 10.3390/life13020510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 01/26/2023] [Accepted: 02/10/2023] [Indexed: 02/15/2023] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive degeneration of upper and lower motor neurons. To study its underlying mechanisms, a variety of models are currently used at the cellular level and in animals with mutations in multiple ALS associated genes, including SOD1, C9ORF72, TDP-43, and FUS. Key mechanisms involved in the disease include excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammatory, and immune reactions. In addition, significant metabolism alterations of various lipids classes, including phospholipids, fatty acids, sphingolipids, and others have been increasingly recognized. Recently, the mechanisms of programmed cell death (apoptosis), which may be responsible for the degeneration of motor neurons observed in the disease, have been intensively studied. In this context, sphingolipids, which are the most important sources of secondary messengers transmitting signals for cell proliferation, differentiation, and apoptosis, are gaining increasing attention in the context of ALS pathogenesis given their role in the development of neuroinflammatory and immune responses. This review describes changes in lipids content and activity of enzymes involved in their metabolism in ALS, both summarizing current evidence from animal models and clinical studies and discussing the potential of new drugs among modulators of lipid metabolism enzymes.
Collapse
|
2
|
Li L, Wang Y, Wang H, Lv L, Zhu ZY. Metabolic responses of BV-2 cells to puerarin on its polarization using ultra-performance liquid chromatography-mass spectrometry. Biomed Chromatogr 2020; 34:e4796. [PMID: 31960437 DOI: 10.1002/bmc.4796] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 01/07/2020] [Accepted: 01/16/2020] [Indexed: 12/22/2022]
Abstract
Microglia are the primary immune cells in the central nervous system with functional plasticity. They can be activated into M1 and M2 phenotypes when neuroinflammation-related diseases occur. M1 phenotype cells produce pro-inflammatory mediators that cause neuroinflammation and the M2 phenotype can secrete anti-inflammatory cytokines that protect neurons from damage. Therefore, inhibiting the M1 phenotype while stimulating the M2 phenotype has been suggested as a potential therapeutic approach for treating neuroinflammation-related diseases. Puerarin has been demonstrated to exert anti-inflammatory and neuroprotective effects. However, the role of puerarin in regulating microglia polarization and its reaction mechanism has not been fully elucidated. In this paper, a metabolomics approach with ultra-performance liquid chromatography-mass spectrometry was performed to investigate the metabolic changes of BV-2 cells in different phenotypes and test the effects of puerarin on polarization. Thirty-nine metabolites were identified as the biomarkers related to the polarization of BV-2 cells and puerarin intervention reverted the content of most of the biomarkers. Our study demonstrated that puerarin could play a key role in M1/M2 polarization of BV-2 cells from a perspective of metabolomics, and it could regulate the balance between promotion and suppression of inflammation.
Collapse
Affiliation(s)
- Ling Li
- School of Pharmacy, Second Military Medical University, Shanghai, China
| | - Yan Wang
- Department of Pharmacy, Shanghai First People's Hospital Baoshan Branch, Shanghai, China
| | - Hui Wang
- School of Pharmacy, Second Military Medical University, Shanghai, China
| | - Lei Lv
- Department of Pharmacy, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China
| | - Zhen-Yu Zhu
- School of Pharmacy, Second Military Medical University, Shanghai, China
| |
Collapse
|
3
|
Alessenko A, Gutner U, Nebogatikov V, Shupik M, Ustyugov A. The role of lipids in the pathogenesis of lateral amyotrophic sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova 2020; 120:108-117. [DOI: 10.17116/jnevro2020120101108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Gutner UA, Shupik MA, Maloshitskaya OA, Sokolov SA, Rezvykh AP, Funikov SY, Lebedev AT, Ustyugov AA, Alessenko AV. Changes in the Metabolism of Sphingoid Bases in the Brain and Spinal Cord of Transgenic FUS(1-359) Mice, a Model of Amyotrophic Lateral Sclerosis. BIOCHEMISTRY (MOSCOW) 2019; 84:1166-1176. [PMID: 31694512 DOI: 10.1134/s0006297919100055] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The aim of this study was to evaluate changes in the content of sphingoid bases - sphingosine (SPH), sphinganine, and sphingosine-1-phosphate (SPH-1-P) - and in expression of genes encoding enzymes involved in their metabolism in the brain structures (hippocampus, cortex, and cerebellum) and spinal cord of transgenic FUS(1-359) mice. FUS(1-359) mice are characterized by motor impairments and can be used as a model of amyotrophic lateral sclerosis (ALS). Lipids from the mouse brain structures and spinal cord after 2, 3, and 4 months of disease development were analyzed by chromatography/mass spectrometry, while changes in the expression of the SPHK1, SPHK2, SGPP2, SGPL1, ASAH1, and ASAH2 genes were assayed using RNA sequencing. The levels of SPH and sphinganine (i.e., sphingoid bases with pronounced pro-apoptotic properties) were dramatically increased in the spinal cord at the terminal stage of the disease. The ratio of the anti-apoptotic SPH-1-P to SPH and sphinganine sharply reduced, indicating massive apoptosis of spinal cord cells. Significant changes in the content of SPH and SPH-1-P and in the expression of genes related to their metabolism were found at the terminal ALS stage in the spinal cord. Expression of the SGPL gene (SPH-1-P lyase) was strongly activated, while expression of the SGPP2 (SPH-1-P phosphatase) gene was reduced. Elucidation of mechanisms for the regulation of sphingolipid metabolism in ALS will help to identify molecular targets for the new-generation drugs.
Collapse
Affiliation(s)
- U A Gutner
- Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, 119991, Russia
| | - M A Shupik
- Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, 119991, Russia
| | - O A Maloshitskaya
- Lomonosov Moscow State University, Faculty of Chemistry, Moscow, 119999, Russia
| | - S A Sokolov
- Lomonosov Moscow State University, Faculty of Chemistry, Moscow, 119999, Russia
| | - A P Rezvykh
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia
| | - S Yu Funikov
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia
| | - A T Lebedev
- Lomonosov Moscow State University, Faculty of Chemistry, Moscow, 119999, Russia
| | - A A Ustyugov
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow Region, 142432, Russia
| | - A V Alessenko
- Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, 119991, Russia.
| |
Collapse
|
5
|
Torkhovskaya TI, Zakharova TS, Korotkevich EI, Ipatova OM, Markin SS. Human Blood Plasma Lipidome: Opportunities and Prospects of Its Analysis in Medical Chemistry. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2019. [DOI: 10.1134/s106816201905011x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
6
|
Horid’ko TM, Kosiakova HV, Berdyshev AG. Preventive effect of N-stearoylethanolamine on memory disorders, blood and brain biochemical parameters in rats with experimental scopolamine-induced cognitive impairment. UKRAINIAN BIOCHEMICAL JOURNAL 2018. [DOI: 10.15407/ubj90.06.097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
7
|
Bachurin SO, Gavrilova SI, Samsonova A, Barreto GE, Aliev G. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res 2018; 129:216-226. [DOI: 10.1016/j.phrs.2017.11.021] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 11/15/2017] [Accepted: 11/17/2017] [Indexed: 01/16/2023]
|
8
|
Li J, Liu Y, Li W, Wang Z, Guo P, Li L, Li N. Metabolic profiling of the effects of ginsenoside Re in an Alzheimer's disease mouse model. Behav Brain Res 2017; 337:160-172. [PMID: 28927718 DOI: 10.1016/j.bbr.2017.09.027] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 09/10/2017] [Accepted: 09/16/2017] [Indexed: 12/12/2022]
Abstract
Alzheimer's disease (AD) is one of the major neurological diseases among the elderly, and there are presently no approved treatments that can slow its progression. It has been reported that ginsenoside Re (G-Re), an active pharmacological component of ginseng, can ameliorate the symptoms of AD, but the underlying mechanisms are not clear. The current study was designed to test the effects of G-Re by investigating the metabolite profiles of AD mice. An AD animal model was induced by intracerebroventricular injection of β-amyloid in Kunming mice. Model mice were administered G-Re intragastrically (4mg/kg/day as a high dose and 1mg/kg/day as a low dose) for 30days. Cognitive function of the mice was tested using a Morris water maze, and pathological changes in the brain tissue were assessed by immunohistochemistry. Global metabolite profiling using ultra performance liquid chromatography-mass spectrometry was carried out to identify the metabolites that were differentially expressed in the plasma of mice. A total of 10 potential biomarkers were identified in AD mice. The peak intensities of tryptophan, hexadecasphinganine, phytosphingosine, and various lysophosphatidylcholines were lower whereas that of phenylalanine was higher in the AD mice than in the control mice. G-Re treatment (4mg/kg) affected all of these metabolic pathways. This is the first metabonomics study to biochemically profile the plasma metabolic pathways of AD animals affected by G-Re. These outcomes provide reliable evidence that illuminates the biochemical mechanisms of AD and facilitates investigation of the therapeutic benefits of G-Re in AD treatment.
Collapse
Affiliation(s)
- Jingyuan Li
- Department of Gerontology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China
| | - Ying Liu
- Department of Emergency Medicine, Laboratory of PLA Wound and Trauma Center, The General Hospital of Shenyang Military, Shenyang 110016, Liaoning, China
| | - Wei Li
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China
| | - Zhe Wang
- Department of Gerontology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China
| | - Pan Guo
- Department of Gerontology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China
| | - Lin Li
- Department of Neurology, The Second Affiliated Hospital of Shenyang Medical College, Shenyang 110002, Liaoning, China
| | - Naijing Li
- Department of Gerontology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China.
| |
Collapse
|
9
|
Alessenko A, Bachurin S, Gurianova S, Karatasso Y, Shevtsova E, Shingarova L. Tumor necrosis factor-alpha - potential target for neuroprotector dimebon. ACTA ACUST UNITED AC 2016; 62:418-25. [DOI: 10.18097/pbmc20166204418] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Dimebon (Dimebolin) is an antihistamine drug which has been used in Russia since 1983. Recently Dimebolin has attracted renewed interest after being shown to have positive effects on persons suffering from Alzheimer's disease. Animal studies have shown that dimebon acts through multiple mechanisms, both blocking the action of neurotoxic beta-amyloid peptides and inhibiting L-type calcium channels, modulating the action of AMPA and NMDA glutamate receptors. Our experiments with cell culture L929 and mice have shown that dimebon may exert its neuroprotective effect by blocking cytotoxic signals induced by proinflammatory cytokines such as TNF-a which are believed to play a central role in Alzheimer's disease. Dimebon (10 mg/ml) protected mouse fibroblasts L929 against the toxic action of TNF-a. Our study included 65 male mice. TNF-a (10 mg per mouse), dimebon (0,2 mg/kg) and their combination were injected intraperitonealy. Changes in the level of molecular species of sphingomyelin and galactosyl ceramide in hippocampus, cerebellum and cerebral cortex within 30 min, 2 h, 4 h, and 24 h after injection were detected by chromato-mass-spectrometry. Maximal changes in sphingomyelin and galactosyl ceramides contents of different molecular species after single TNF-a administration were found in the hippocampus, and were less expressed in the cerebral cortex and cerebellum after 24 h. Dimebon itself did not induce changes in the sphingolipid spectrum in brain sections, but protected them against disorders induced by TNF-a in the brain. Modern strategies in the search of new therapeutic approaches are based on the multitarget properties of new drugs. According to our results TNF-a may serve as a new target for dimebon.
Collapse
Affiliation(s)
- A.V. Alessenko
- Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia
| | - S.O. Bachurin
- Institute of Physiologically Active Substances of the Russian Academy of Sciences, Chernogolovka, Russia
| | - S.V. Gurianova
- Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
| | - Y.O. Karatasso
- Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia
| | - E.F. Shevtsova
- Institute of Physiologically Active Substances of the Russian Academy of Sciences, Chernogolovka, Russia
| | - L.N. Shingarova
- Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
10
|
Lokhov PG, Maslov DL, Balashova EE, Trifonova OP, Medvedeva NV, Torkhovskaya TI, Ipatova OM, Archakov AI, Malyshev PP, Kukharchuk VV, Shestakova EA, Shestakova MV, Dedov II. Mass spectrometry analysis of blood plasma lipidome as the method of disease diagnostics, evalution of effectiveness and optimization of drug therapy. BIOCHEMISTRY (MOSCOW) SUPPLEMENT SERIES B: BIOMEDICAL CHEMISTRY 2015. [DOI: 10.1134/s1990750815020109] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
11
|
Li N, Liu Y, Li W, Zhou L, Li Q, Wang X, He P. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. J Ginseng Res 2015; 40:9-17. [PMID: 26843817 PMCID: PMC4703800 DOI: 10.1016/j.jgr.2015.04.006] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 04/20/2015] [Accepted: 04/20/2015] [Indexed: 01/10/2023] Open
Abstract
Background Alzheimer's disease (AD) is a progressive brain disease, for which there is no effective drug therapy at present. Ginsenoside Rg1 (G-Rg1) and G-Rg2 have been reported to alleviate memory deterioration. However, the mechanism of their anti-AD effect has not yet been clearly elucidated. Methods Ultra performance liquid chromatography tandem MS (UPLC/MS)-based metabolomics was used to identify metabolites that are differentially expressed in the brains of AD mice with or without ginsenoside treatment. The cognitive function of mice and pathological changes in the brain were also assessed using the Morris water maze (MWM) and immunohistochemistry, respectively. Results The impaired cognitive function and increased hippocampal Aβ deposition in AD mice were ameliorated by G-Rg1 and G-Rg2. In addition, a total of 11 potential biomarkers that are associated with the metabolism of lysophosphatidylcholines (LPCs), hypoxanthine, and sphingolipids were identified in the brains of AD mice and their levels were partly restored after treatment with G-Rg1 and G-Rg2. G-Rg1 and G-Rg2 treatment influenced the levels of hypoxanthine, dihydrosphingosine, hexadecasphinganine, LPC C 16:0, and LPC C 18:0 in AD mice. Additionally, G-Rg1 treatment also influenced the levels of phytosphingosine, LPC C 13:0, LPC C 15:0, LPC C 18:1, and LPC C 18:3 in AD mice. Conclusion These results indicate that the improvements in cognitive function and morphological changes produced by G-Rg1 and G-Rg2 treatment are caused by regulation of related brain metabolic pathways. This will extend our understanding of the mechanisms involved in the effects of G-Rg1 and G-Rg2 on AD.
Collapse
Affiliation(s)
- Naijing Li
- Department of Gerontology, The Shengjing Affiliated Hospital, China Medical University, Shenyang, China
| | - Ying Liu
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Wei Li
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Ling Zhou
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Qing Li
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Xueqing Wang
- Department of Gastroenterology, The Shengjing Affiliated Hospital, China Medical University, Shenyang, China
| | - Ping He
- Department of Gerontology, The Shengjing Affiliated Hospital, China Medical University, Shenyang, China
| |
Collapse
|
12
|
Lokhov P, Maslov D, Balashova E, Trifonova O, Medvedeva N, Torkhovskaya T, Ipatova O, Archakov A, Malyshev P, Kukharchuk V, Shestakova E, Shestakova M, Dedov I. Mass spectrometry analysis of blood plasma lipidome as method of disease diagnostics, evuation of effectiveness and optimization of drug therapy. ACTA ACUST UNITED AC 2015; 61:7-18. [DOI: 10.18097/pbmc20156101007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A new method for the analysis of blood lipid based on direct mass spectrometry of lipophilic low molecular weight fraction of blood plasma has been considered. Such technique allows quantification of hundreds of various types of lipids and this changes existing concepts on diagnostics of lipid disorders and related diseases. The versatility and quickness of the method significantly simplify its wide use. This method is applicable for diagnostics of atherosclerosis, diabetes, cancer and other diseases. Detalization of plasma lipid composition at the molecular level by means of mass spectrometry allows to assess the effectiveness of therapy and to optimize the drug treatment of cardiovascular diseases by phospholipid preparations.
Collapse
Affiliation(s)
- P.G. Lokhov
- Institute of Biomedical Chemistry, Moscow, Russia
| | - D.L. Maslov
- Institute of Biomedical Chemistry, Moscow, Russia
| | | | | | | | | | - O.M. Ipatova
- Institute of Biomedical Chemistry, Moscow, Russia
| | | | - P.P. Malyshev
- Russian Cardiology Research and Production Complex, Moscow, Russia
| | - V.V. Kukharchuk
- Russian Cardiology Research and Production Complex, Moscow, Russia
| | | | | | - I.I. Dedov
- Endocrinology Research Centre, Moscow, Russia
| |
Collapse
|
13
|
García-Barros M, Coant N, Truman JP, Snider AJ, Hannun YA. Sphingolipids in colon cancer. Biochim Biophys Acta Mol Cell Biol Lipids 2013; 1841:773-82. [PMID: 24060581 DOI: 10.1016/j.bbalip.2013.09.007] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2013] [Revised: 09/12/2013] [Accepted: 09/16/2013] [Indexed: 01/28/2023]
Abstract
Colorectal cancer is one of the major causes of death in the western world. Despite increasing knowledge of the molecular signaling pathways implicated in colon cancer, therapeutic outcomes are still only moderately successful. Sphingolipids, a family of N-acyl linked lipids, have not only structural functions but are also implicated in important biological functions. Ceramide, sphingosine and sphingosine-1-phosphate are the most important bioactive lipids, and they regulate several key cellular functions. Accumulating evidence suggests that many cancers present alterations in sphingolipids and their metabolizing enzymes. The aim of this review is to discuss the emerging roles of sphingolipids, both endogenous and dietary, in colon cancer and the interaction of sphingolipids with WNT/β-catenin pathway, one of the most important signaling cascades that regulate development and homeostasis in intestine. This article is part of a Special Issue entitled New Frontiers in Sphingolipid Biology.
Collapse
Affiliation(s)
- Mónica García-Barros
- Department of Medicine and the Stony Brook Cancer Center, Health Science Center, Stony Brook University, 101 Nicolls Road, T15, 023, 11794, Stony Brook, NY, USA.
| | - Nicolas Coant
- Department of Medicine and the Stony Brook Cancer Center, Health Science Center, Stony Brook University, 101 Nicolls Road, T15, 023, 11794, Stony Brook, NY, USA.
| | - Jean-Philip Truman
- Department of Medicine and the Stony Brook Cancer Center, Health Science Center, Stony Brook University, 101 Nicolls Road, T15, 023, 11794, Stony Brook, NY, USA.
| | - Ashley J Snider
- VAMC Northport, 79 Middleville Road, Northport, NY, USA, Health Science Center, Stony Brook University, Stony Brook, NY, USA.
| | - Yusuf A Hannun
- Department of Medicine and the Stony Brook Cancer Center, Health Science Center, Stony Brook University, 101 Nicolls Road, T15, 023, 11794, Stony Brook, NY, USA.
| |
Collapse
|